fbpx

Emovi CSO Dr. Alexandre Fuentes Presents “Functional Return to Duty Decision Making Post MTBI and Musculoskeletal Injury” During 2019 MHSRS

Fuentes’ poster covers the addition of an objective biomechanical assessment into the management of knee osteoarthritis for civilian patients.

Montreal, Quebec (August 6, 2019) Emovi, Inc., manufacturer of the KneeKG device, today announced that Chief Science Officer, Dr. Alexandre Fuentes will present at the Military Health System Research Symposium (MHSRS), which takes place Aug 19-21, 2019 in Kissimmee, Florida. Dr. Fuentes’ abstract was selected after a rigorous review process among several thousand applicants making the presentation one among a small, elite group.

The MHSRS is the Department of Defense’s premier scientific meeting which provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives.

Dr. Fuentes will present research results which indicates that integrating data from an objective biomechanical evaluation using KneeKG, into the management of knee osteoarthritis patients, can significantly improve their pain, function and satisfaction levels.

Dr. Fuentes’ poster presents information about knee osteoarthritis (KOA), a leading cause of disability discharge from the military for more than a decade. It will also present results from a randomized, controlled trial involving Knee Kinesiographies by KneeKG™, Emovi’s flagship medical device and the first device that enables doctors to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing.

Although clinical guidelines for KOA recommends conservative therapies such as biomechanical interventions, exercise, and strength training, a Knee Kinesiography by KneeKG identifies the gaps between guideline recommendations and actual practice patterns.

In contrast to static information provided by x-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies motion of impaired knees, allowing healthcare providers to determine the most suitable care to restore optimal knee function instead of the current process of elimination method. KneeKG is revolutionizing existing knee assessment techniques as it provides motion data so a healthcare provider can evaluate the knee and provide strategic treatment options. “Active-duty military personnel are known to have significantly higher rates of KOA compared to the general population, which is a burdensome and career-limiting condition. By assessing mechanical deficiencies linked with knee osteoarthritis, it is possible to improve or mitigate pain, function, and satisfaction levels compared to the current medical management in a civilian health system,” said Fuentes. “Based on our research, we highly recommend a similar study in a military health care system be considered.”

The presentation will be available August 20 from 1000 to 1200 local time during Poster Session 1, and then transfered to Emovi’s booth #1015 for the remainder of the conference for those that wish to view and discuss with Emovi team members at hand.

About Emovi Inc.
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore patient quality of life. In partnership with the Quebec university research community, including the CRCHUM and École de technologie supérieure (ÉTS), Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive license to commercialize the KneeKG in several countries.

kneekinesiography.com